Pregnancy outcome following gestational exposure to azithromycin 英文参考文献.docVIP

BMC Pregnancy and Childbirth BioMedCentral Research article Open Access Pregnancy outcome following gestational exposure to azithromycin Moumita Sarkar1,2, Cindy Woodland C1,3, Gideon Koren1,2,3 and Adrienne RN Einarson*1 Address: 1The Motherisk Program, The Hospital for Sick Children, Toronto, Canada, 2Department of Pharmaceutical Sciences, The University of Toronto, Canada and 3Department of Pharmacology and Toxicology, The University of Toronto, Canada Email: Moumita Sarkar - moumita.sarkar@sickkids.ca; Cindy Woodland C - c.woodland@utoronto.ca; Gideon Koren - gkoren@sickkids.ca; Adrienne RN Einarson* - einarson@sickkids.ca * Corresponding author Published: 30 May 2006 Received: 03 February 2006 Accepted: 30 May 2006 BMC Pregnancy and Childbirth 2006, 6:18 doi:10.1186/1471-2393-6-18 This article is available from: /1471-2393/6/18 ? 2006 Sarkar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Azithromycin is an azalide antibiotic with an extensive range of indications and has become a common treatment option due to its convenient dosing regimen and therapeutic advantages. Human studies addressing gestational use of azithromycin have primarily focused on antibiotic efficacy rather than fetal safety. Our primary objective was to evaluate the possibility of teratogenic risk following gestational exposure to azithromycin. Methods: There were 3 groups of pregnant women enrolled in our study: 1) women who took azithromycin. 2) women exposed to non-teratogenic antibiotics for similar indications, and 3) women exposed to non-teratogenic agents. They were matched for gestational age at time of call, maternal age, cigarette and alcohol consumption. Rates of